Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab

Gracia Cazaña, Tamara (Universidad de Zaragoza) ; Riera Monroig, Josep ; Izu, Rosa ; Yanguas, Ignacio ; Lorda Espés, Marta ; Sánchez Salas, María Pilar ; García Gil, Miguel Fernando ; Navarro Bielsa, Alba ; Aldea Manrique, Beatriz ; Almenara Blasco, Manuel (Universidad de Zaragoza) ; García-Latasa de Araníbar, Francisco Javier ; Fuentelsaz, Victoria ; Morales Callaghan, Ana (Universidad de Zaragoza) ; Ara-Martín, Mariano (Universidad de Zaragoza)

Resumen: Background: The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians. Objectives: To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer. Methods: We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis. Results: Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected. Limitations: Modest sample size and the retrospective nature of the study. Conclusion: Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.

Idioma: Inglés

DOI: 10.1016/j.jdin.2024.02.019

Año: 2024

Publicado en: JAAD International 16 (2024), 66-71
ISSN: 2666-3287

Factor impacto CITESCORE: 4.3 - Dermatology (Q2)

Factor impacto SCIMAGO: 0.896 - Dermatology (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Dermatología (Dpto. Medicina, Psiqu. y Derm.)